CN101862360A - New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer - Google Patents
New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer Download PDFInfo
- Publication number
- CN101862360A CN101862360A CN201010181257A CN201010181257A CN101862360A CN 101862360 A CN101862360 A CN 101862360A CN 201010181257 A CN201010181257 A CN 201010181257A CN 201010181257 A CN201010181257 A CN 201010181257A CN 101862360 A CN101862360 A CN 101862360A
- Authority
- CN
- China
- Prior art keywords
- gastric
- radix achyranthis
- achyranthis bidentatae
- precancerous lesion
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a new application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer, belonging to the field of medicines. The invention aims to provide a new application of radix achyranthis bidentatae in the medicines for preventing and/or treating gastric precancerous lesion and preventing and treating gastric malignant tumors. Active portion of achyranthes are prepared by adopting an organic solvent extraction method. The animal experiment proves that achyranthes can obviously inhibit the atypical hyperplasia of gastric mucosa cells, inhibit the precancerous lesion and prevent the occurrence of gastric malignant tumors, which are not reported and applied in traditional researches and clinics, thus the invention has uniqueness and novelty. The achyranthes has wide resources and simple and convenient extraction methods and can be prepared into various dosage forms. Gastric cancer is one of common malignant tumors in China, the morbidity of the gastric cancer in China ranks first among all tumors so as to demand large medicines in clinic. Thus, the invention has very strong practicability and has very wide application prospects in the aspects of preventing and/or treating gastric mucosa precancerous lesion and the occurrence of gastric malignant tumors.
Description
One, technical field
The invention belongs to field of medicaments.
Two, background technology
Radix Achyranthis Bidentatae is the dry root of Amaranthaceae herbaceos perennial Radix Achyranthis Bidentatae (Achyranthes bidentata B1), and this pedals another name Radix Achyranthis Bidentatae, cattle stem, Radix Achyranthis Bidentatae, foot etc., and property is flat, and the sweet in the mouth picric acid is returned the Liver and kidney warp.Have blood circulation promoting and blood stasis dispelling, invigorating the liver and kidney, bone and muscle strengthening, inducing diuresis for treating stranguria syndrome, conducting blood to flow downwards effect.Radix Achyranthis Bidentatae is the conventional Chinese medicine of expelling wind and removing dampness, blood circulation promoting and blood stasis dispelling and treatment gynecological diseases, diseases such as clinical menoxenia, dysmenorrhea, amenorrhea, postpartum stagnation stomachache, traumatic injury and the soreness of waist and knee joint that is used for stagnation of blood stasis, weakness of the lower extremities, hematuria, dysuria, Urethra astringent pain.In recent years its Pharmacological action study has been obtained new progress, thought that it has effects such as antiviral, immunomodulating, antalgic and inflammation relieving, defying age, blood pressure lowering.Clinically, the Chinese medicine compound that contains Radix Achyranthis Bidentatae is made into external or oral agents is used.Studies have shown that, Radix Achyranthis Bidentatae is used for the treatment of diseases such as hypertension and laryngopharynx swelling and pain also effect preferably, and consumption, the purposes of Radix Achyranthis Bidentatae continue to increase and widen in the famous Chinese patent medicine such as seven ingredient beard beautifying granule, Babao Kunshun Wan, three two halves medicated wine, three wonderful balls, Rhizoma Gastrodiae Pilulae, Fructus Chaenomelis Pilulae, Aifu Nuangong Wan, PINGGAN SHULUO WAN, ANKUN ZANYU WAN, KANGGU ZENGSHENG WAN, longevity powder, bushen guchi pills, kidney-brain-nourishing tablet, suoyang gujing pills, SHUJIN WAN, comb wind Pain-Stopping Pill.Be again exporting simultaneously, have bigger exploitation and be worth.
Gastric cancer is one of common malignancy, and its sickness rate and mortality rate all occupy the prostatitis of malignant tumor in China.The canceration of gastric epithelial cell is a progressive process, and in the normal experience lasting preventing precancerous lesion of stomach cancer stage for many years, some patient finally can be developed into gastric cancer.Therefore prevent or the treatment gastric precancerous lesion, stoping precancerous lesion to be converted into pernicious gastric cancer is an important channel that prevents and treats gastric cancer, and China's cancer morbidity and patient death rate are significant for reducing.
1. Radix Achyranthis Bidentatae many-sided drug action that has been in the news, but do not see that the research report that prevents and/or treats treatment gastric precancerous lesion aspect is arranged
The Radix Achyranthis Bidentatae that studies have shown that in the past has following effect: (1) analgesic and anti-inflammatory effects: can obviously alleviate dimethylbenzene induced mice ear swelling, Ovum Gallus domesticus album causes acute inflammatory responses such as rat paw edema, can reduce rat agar granuloma quality, mice licks the sufficient time on the prolongation hot plate, the effect of stronger paroxysmal pain antiinflammatory action (2) to cardiovascular system is arranged: have blood vessel dilating, bring high blood pressure down and the effect of study of anti-atherogenic effect (3) to the uterus: all there are appreciable stimulating action and antifertility, antiearly pregnancy and anti-implantation effect in rats in vitro uterus under the different physiological statuss.(4) enhancing immunity: improve the mouse spleen and the thymus index of immunologic hypofunction, the leukopenia of antagonism mice improves T/B lymhocyte transformation rate and macrophage phagocytic function, promotes the formation of hemolysis plaque.(5) diuresis: Radix Achyranthis Bidentatae decocting liquid has slight diuresis.(6) antitumor action: indivedual bibliographical informations have been arranged Radix Cyathulae or Inokopolyose has certain inhibitory action to S180 sarcoma and H22 hepatocarcinoma and Lewis lung cancer.But domestic and foreign literature there is no document record or formal disclosed research report that relevant Radix Achyranthis Bidentatae is used to prevent and treat the gastric mucosa precancerous lesion.
2. the Radix Achyranthis Bidentatae clinical practice is extensive, but does not see that it is preventing and/or treating the application of treatment aspect the gastric precancerous lesion
Radix Achyranthis Bidentatae is extensive in clinical practice, both can use separately, also can form compound recipe with other drug and use, and oral, external preparation use is arranged.It is used for more the stasis of blood stagnate amenorrhea, puerperal stasis of blood pain, fall pounce on that the pain of injury, soreness of waist and knee joint, sufficient knee joint wither that soft unable, haematemesis, epistaxis, gingival swelling and pain, headache are dizzy, diseases such as dysuria, the puckery pain of pouring drop and hematuria, also be used for defying age, blood pressure lowering and treatment gastritis and gastric ulcer aspect in recent years.So far, do not see that Radix Achyranthis Bidentatae is the treatment gastric precancerous lesion clinical practice report that the compound recipe of main component is used for the related preparations of any route of administration separately or with the Radix Achyranthis Bidentatae.
Three, summary of the invention
In order to make full use of the Radix Achyranthis Bidentatae resource, enlarge the clinical practice of Radix Achyranthis Bidentatae, the inventor adopts chemical carcinogen to induce gastric mucosa of rat hyperplasia of prostate/precancerous lesion/stomach malignant cancer model, studied the generation evolution of the inductive gastric mucosa of rat hyperplasia of prostate of Radix Achyranthis Bidentatae extract inhibition chemical carcinogen → gastric mucosa precancerous lesion → stomach malignancy, the effect that prevention gastric precancerous lesion and pernicious gastric cancer take place, the proof Radix Achyranthis Bidentatae can obviously suppress the papillary hyperplasia of gastric mucosa, alleviate the precancerous lesions such as atypical hyperplasia of stomach basal cell, reduce the gastric tumor growth, reduce generation rate of malignant tumour.Proved that Radix Achyranthis Bidentatae has the control gastric precancerous lesion, the new role that prevention stomach malignant cancer takes place.Therefore, the purpose of this invention is to provide Radix Achyranthis Bidentatae and prevent and/or treat gastric precancerous lesion, prevent and treat the new application in the gastric cancer medicine in preparation.
Technical solution:
Content of the present invention is: provide Radix Achyranthis Bidentatae to prevent and/or treat gastric precancerous lesion in preparation, prevent and treat the new application in the gastric cancer medicine.
Described Radix Achyranthis Bidentatae is the extract of Radix Achyranthis Bidentatae dry root, and its preparation can be taked following method:
Get Radix Achyranthis Bidentatae decoction pieces 1000 gram and add 50% ethanol, reflux, extract, four times adds at every turn that amount of alcohol is respectively 4000,3000,3000,3000ml refluxed 1 hour.Soaked 8～12 hours before refluxing the first time, merge four times backflow, filter, remove insoluble matter, decompression recycling ethanol, and be concentrated into nothing alcohol flavor, and thin up is to 2500ml, and cold preservation filtered more than 24 hours, and clear and bright liquid is concentrated into 1000ml.
Product of the present invention comprises and contains medicine, health product, the foods and cosmetics that relating to of Radix Achyranthis Bidentatae prevents and/or treats the gastric mucosa precancerous lesion, prevents and treats the gastric cancer related application.
Product of the present invention comprises relating to and contains human and the product for animals that relating to of Radix Achyranthis Bidentatae prevents and/or treats the gastric mucosa precancerous lesion, prevents and treats the gastric cancer related application.
Further aspect of the present invention also relates to the human of related application of the precancerous lesion that prevents and/or treats other mucosas such as bladder, cervix uteri, uterus, small intestinal or large intestine, oral cavity, nasopharynx, esophagus etc. and malignant tumor or medicine for animals, health product, foods and cosmetics.
It is active component that further aspect of the present invention also relates to the Radix Achyranthis Bidentatae extract, to prevent and/or treat the gastric mucosa precancerous lesion, to prevent and treat the pharmaceutical composition that gastric cancer is indication.This pharmaceutical composition can be with the extract of the method described in technical solution of the present invention preparation or further refining thing, combines with one or more pharmaceutically acceptable solids or liquid excipient and/or adjuvant, makes to be suitable for any dosage form that the human or animal uses.Route of administration can be intestinal or parenteral route, as: oral, intravenous injection, intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, eye, lung and respiratory tract, skin, vagina, rectum etc.Form of administration can be liquid dosage form, solid dosage forms or semisolid dosage form.Liquid dosage form can be solution (comprising true solution and colloid solution), Emulsion, microemulsion, suspensoid, injection (comprising aqueous injection, injectable powder and transfusion), eye drop, nasal drop, lotion, liniment etc.; Solid preparation can be tablet (comprising ordinary tablet, enteric coatel tablets, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, oral cavity disintegration tablet etc.), capsule (comprising hard capsule, soft capsule, enteric coated capsule), granule, powder, micropill, drop pill, suppository, membrane, paster, the agent of gas (powder) mist, spray etc.; Semi-solid preparation can be ointment, gel, paste etc.Preparation can be made ordinary preparation, also can be slow releasing agent, controlled release agent, targeting preparation and various particulate delivery system.
Advantage that the present invention has and effect:
1. the Radix Achyranthis Bidentatae resource is very extensive, and extracting method is simple, can be made into pharmaceutical preparatioies such as capsule, concentrated pill, granule, tablet, powder, oral liquid, membrane, spray, gel, injection, suspensoid or external preparation.
2. prove through rat test that Radix Achyranthis Bidentatae can obviously suppress the hyperplasia of the inductive rat stomach mucosa of chemical carcinogen, reduce the growth of gastric mucosa papilloma, reduce gastric mucosa precancerous lesion atypical hyperplasia incidence rate, reduce the stomach malignancy incidence rate.Radix Achyranthis Bidentatae medication 10,15,20 during week tumor control rate be respectively 48～57%, 15～45%, 30～49%.On the gastric mucosa of the rat of taking, in volume and obviously minimizing (little) quantitatively, the gastric mucosa smoothness increases visible mamillary tumor than model group, and stomach weight reduces than model group, and statistical significance is arranged.Test is during 10 weeks, and model group precancerous lesion (I～III degree atypical hyperplasia) incidence rate is 83.3%, and pernicious canceration incidence rate is 16.7%.And Radix Achyranthis Bidentatae 1g/kg group only has I～II degree atypical hyperplasia, incidence rate obviously to reduce, and only is 40%, and pernicious canceration incidence rate is 0%.Test is during 20 weeks, and the animal of model group has 80% generation malignant change to become gastric cancer, and Radix Achyranthis Bidentatae 1g/kg group only has 40% animal malignant change.The result shows that Radix Achyranthis Bidentatae has prevention and treatment gastric precancerous lesion, prevents and treats the effect of pernicious gastric cancer.
Four, description of drawings
Accompanying drawing is the gastric mucosa tumor growth situation of modeling each group during 15 weeks.
Have the stomach photo of 5 treated animals, comprise control group, model group, root of bidentate achyranthes 1.0g/kg, root of bidentate achyranthes 2.0g/kg, root of bidentate achyranthes 4.0g/kg
As seen from the figure, the control group mucosa surface is smooth, and normal gauffer is arranged, but unpolarized swollen thing growth. Model group stomach lining face has a large amount of papilloma growths, and tumour is cauliflower-shaped to the gastral cavity projection, and there are localized bleeding, necrosis in the animal tumor surface that has; Because tumor growth, whole body of stomach is long-pending obviously to be increased than control group. The body of stomach of root of bidentate achyranthes 1.0g/kg, 2.0g/kg, 4.0g/kg dosage group is long-pending all obviously to be reduced than model group, and the tumour number of mucosa surface and size all reduce than model group, and the mucous membrane district of more not bearing tumor is arranged, and increase in ganoid zone.
Five, the specific embodiment
1. the preparation method of Radix Achyranthis Bidentatae
Get Radix Achyranthis Bidentatae decoction pieces 1000 gram and add 50% ethanol, reflux, extract, four times adds at every turn that amount of alcohol is respectively 4000,3000,3000,3000ml refluxed 1 hour.Soaked 8～12 hours before refluxing the first time, merge four times backflow, filter, remove insoluble matter, decompression recycling ethanol, and be concentrated into nothing alcohol flavor, and thin up is to 2500ml, and cold preservation filtered more than 24 hours, and clear and bright liquid is concentrated into 1000ml.
2. animal experiment method
The SD rat by being divided into 4 groups at random, is respectively: 1. normal group; 2. model group (Aristolochic Acid 10mg/kg causes gastric mucosa hyperplasia of prostate → gastric mucosa precancerous lesion → stomach malignancy model); 3. Radix Achyranthis Bidentatae 1g/kg organizes; 4. Radix Achyranthis Bidentatae 2g/kg organizes.5. Radix Achyranthis Bidentatae 4g/kg organizes.Except matched group, 2.～5. organize and irritate the modeling medicine that stomach once contains Aristolochic Acid 10mg/kg equal the next day, until 20 weeks.Except irritating stomach modeling medicine, model group is also irritated stomach every day and is given distilled water 5ml/kg.The Radix Achyranthis Bidentatae that each dosage group filling stomach of Radix Achyranthis Bidentatae gives various dose is tried thing 5ml/kg.Be total to 20 weeks of administration.Respectively at 10,15,20 weeks after the administration getting 1/3 sacrifice of animal, win the stomach of every animal, with electronic analytical balance weighing stomach weight; According to the body weight of every animal, conversion stomach index.Calculate and respectively organize tumor control rate and tamor index suppression ratio.
Stomach index (stomach weight/100g body weight)=stomach weight g/ body weight g * 100
Each organizes tumor weight (g)=test group stomach weight-matched group stomach weight
Tumor control rate (%)=(medication group tumor weight-model group tumor weight)/model group tumor weight * 100
Tamor index suppression ratio (%)=(medication group tamor index-model group tamor index)/(model group tamor index-matched group tamor index) * 100
Then stomach is fixed with 10% neutral formalin, with paraffin embedding, section.Adopt HE (Haematoxylin ﹠amp; Eosin) dyeing is carried out tectology with microscope and is observed, and the number of animals that gastric mucosa papillary hyperplasia, gastric mucosa precancerous lesion (I, II, III degree atypical hyperplasia) and pernicious gastric cancer take place takes place each group of record.
3. result of the test
3.1 Radix Achyranthis Bidentatae is to the prevention and the therapeutical effect of tumor growth
Adopt Aristolochic Acid 10mg/kg 10 weeks of modeling, as seen the gastric mucosa of rat promptly has the multiple papillomatosis growth, and tumor weight reaches 1.08g, and tamor index is 0.28; After 15,20 weeks of modeling, tumor weight is respectively 1.05,1.59g, and tamor index is respectively 0.32,0.29.Radix Achyranthis Bidentatae 1.0,2.0,4.0g/kg dosage group reach 48.15～57.4% at the tumor control rate of medication during 10 weeks; Tumor control rate is that 30.8～49.1%. result shows that Radix Achyranthis Bidentatae has the effect of tangible prophylaxis of tumours growth during 20 weeks.The results are shown in Table 1-3.
10 all stomach weight/coefficient ratio after table 1 administration
Annotate: (1) tumor control rate (%)=(model group stomach weight-Radix Achyranthis Bidentatae group stomach weight)/(model group stomach weight-matched group stomach weight) * 100
(2) tamor index suppression ratio (%)=(model group stomach index-Radix Achyranthis Bidentatae group stomach index)/(model group stomach index-matched group stomach index) * 100
(3) with matched group relatively, each group of Radix Achyranthis Bidentatae extract and model group relatively,
*P＜0.05;
*P＜0.01;
* *P＜0.001 (following table is identical)
15 all stomach weight/coefficient ratio after table 2 administration
Annotate: with table 1
20 all stomach weight/coefficient ratio after table 3 administration
Annotate: with table 1
2.2 Radix Achyranthis Bidentatae prevention gastric precancerous lesion and the prevention and the therapeutical effect that prevent the precancerous lesion malignant change
Adopt the pathological tissue morphological examination, the result shows that test is during 10 weeks, and model group precancerous lesion (I～III degree atypical hyperplasia) incidence rate is 83.3%, and pernicious canceration incidence rate is 16.7%.And Radix Achyranthis Bidentatae 1.0,2.0g/kg group only has I～II degree atypical hyperplasia, precancerous lesion incidence rate obviously to reduce, and is respectively 40%, 60%, and the precancerous lesion suppression ratio is respectively 52.0%, 28.0%.The pernicious canceration incidence rate of these two dosage groups is 0%.In 20 whens week of test, the animal of model group has 80% malignant change takes place to become gastric cancer, and Radix Achyranthis Bidentatae 1.0,2.0,4.0g/kg group only have the pernicious gastric cancer that becomes of 40～50% animals, suppression ratio respectively 37.5～50%.The result shows that Radix Achyranthis Bidentatae has prevention and treatment gastric precancerous lesion, reduces the effect of pernicious gastric cancer incidence rate.The results are shown in Table 4.
The result that table 4 Radix Achyranthis Bidentatae preventing/treating gastric precancerous lesion and prevention gastric cancer take place
Claims (6)
1. Radix Achyranthis Bidentatae is used for preventing and/or treating the application of the medicine of gastric mucosa precancerous lesion and gastric cancer.
2. application according to claim 1 is characterized in that described Radix Achyranthis Bidentatae is decocting liquid, distillate, volatile oil or the extractive with organic solvent of the root of Radix Achyranthis Bidentatae.
3. according to right 1 described application, it is characterized in that described drug products comprises the pharmaceutical composition that contains Radix Achyranthis Bidentatae.
4. according to claim 1,2,3, it is characterized in that described drug products comprises medicine, health product, food, cosmetics.
5. according to claim 1,2,3,4, it is characterized in that described drug products comprises capsule, concentrated pill, granule, tablet, powder, suspensoid, oral liquid, gel, spray, nasal drop, eye drop, membrane, injection.
6. according to claim 1,2,3,4,5, it is characterized in that described drug products comprises human and for animals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010181257A CN101862360A (en) | 2010-05-25 | 2010-05-25 | New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010181257A CN101862360A (en) | 2010-05-25 | 2010-05-25 | New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101862360A true CN101862360A (en) | 2010-10-20 |
Family
ID=42954419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010181257A Pending CN101862360A (en) | 2010-05-25 | 2010-05-25 | New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862360A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526431A (en) * | 2012-03-29 | 2012-07-04 | 翟西菊 | Traditional Chinese medicine preparation for treating gastric cancer and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371909A (en) * | 2008-10-20 | 2009-02-25 | 郝全得 | Medicine for treating carcinoma of stomach and preparation method thereof |
-
2010
- 2010-05-25 CN CN201010181257A patent/CN101862360A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371909A (en) * | 2008-10-20 | 2009-02-25 | 郝全得 | Medicine for treating carcinoma of stomach and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《中华微生物学和免疫学杂志》 20050531 胡洁等 中药牛膝提取物抗肿瘤活性的初步研究 第415-418页 1-6 第25卷, 第5期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526431A (en) * | 2012-03-29 | 2012-07-04 | 翟西菊 | Traditional Chinese medicine preparation for treating gastric cancer and preparation method |
| CN102526431B (en) * | 2012-03-29 | 2013-10-16 | 翟西菊 | Traditional Chinese medicine preparation for treating gastric cancer and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN103463539A (en) | Drug for treating eczema, and preparation method and use thereof | |
| CN101632750B (en) | Chinese medicinal composition for replenishing essence, filling marrow, boosting kidney and strengthening yang and preparation method thereof | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN103463297B (en) | A kind of Chinese medicine composition for the treatment of eczema scrotum and its production and use | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN102218127B (en) | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof | |
| CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN105194271A (en) | Traditional Chinese medicine preparation for treating advanced breast cancer by virtue of combined chemotherapy | |
| CN101862360A (en) | New application of achyranthes for preparing medicines for preventing and/or treating gastric precancerous lesion and gastric cancer | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN103394002A (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN105456815A (en) | Traditional Chinese medicine for inhibiting tumors and preparation method of traditional Chinese medicine | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN115137767B (en) | Traditional Chinese medicine composition for treating ischemic vasculitis caused by cold deficiency syndrome and preparation method thereof | |
| CN105998218A (en) | Pharmaceutical composition for treating female chloasma | |
| CN1053381C (en) | Drug for promoting puerperal physiological recovery and curing postpartum disease | |
| CN106074787A (en) | The pharmaceutical composition for the treatment of women chloasma | |
| CN104606465A (en) | Medicine for treating acute pharyngitis and preparation method for medicine | |
| CN105250576A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20101020 |